Monday, October 3, 2022


Biotechnology News Magazine

GenScript Launches Expedited mRNA Service for Research and Pre-Clinical Applications

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

GenScript USA Inc., the world’s leading life-science research tools and services provider, announced the availability of a new research use only (RUO) and pre-clinical messenger RNA (mRNA) synthesis service for biopharma research and development teams. By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks.

mRNA provides new therapeutic opportunities for a range of diseases, and scientists need expedited, access to robust, custom mRNA to synthesize the proteins used to engineer personalized medicines. But, until now, development of mRNA involved contracting with several different specialist suppliers.

In contrast, GenScript’s IVT mRNA service spans the entire workflow, from gene synthesis to mRNA production. This simple and expedited mRNA manufacturing workflow expands the possibilities for personalized medicines such as patient-specific cancer vaccines or protein replacement for rare diseases.

“GenScript brings decades of deep technical expertise and a reputation for routinely producing customized nucleic acids for biopharma, academic, and industry clients worldwide,” said Ray Chen, PhD, president of GenScript USA Life Science Group. “The new IVT mRNA production service solves mRNA researchers’ challenges of sourcing and communicating among multiple vendors and de-risks the synthesis of highly optimized mRNA designs.”

Service highlights

GenScript accelerates mRNA research with optimized mRNA production workflow — from gene to mRNA in 6-8 weeks

Eliminates the need to provide mRNA expression vectors: just provide open reading frames (ORFs); GenScript will manage all the steps to successful custom mRNA synthesis
GenScript’s integrated gene synthesis, linearization, and IVT process ensures high mRNA integrity and uniform poly(A) tails which results in enhanced expression efficiency.
mRNAs produced at GenScript are optimized with our proprietary production platform, ensuring the quality and expression efficiency of your mRNA.

Where to learn more

Visit GenScript’s IVT mRNA services information page.
Download the GenScript IVT mRNA therapy modalities infographic poster.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine